These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8477114)

  • 21. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
    Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S
    Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.
    Brearley C; Priestley A; Leighton-Scott J; Christen M
    BMC Clin Pharmacol; 2007 Oct; 7():10. PubMed ID: 17922895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad variability in pharmacokinetics of GH following rhGH injections in children.
    Lundberg E; Andersson B; Kriström B; Rosberg S; Albertsson-Wikland K
    Growth Horm IGF Res; 2018 Jun; 40():61-68. PubMed ID: 29422321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative bioavailability of two drug products of somatropin obtained from either the milk of transgenic cows or bacterial culture.
    Farías J; Feleder E; González E; Halabe K; Criscuolo ME; Bergadá I; Diez RA
    Horm Res Paediatr; 2010; 73(4):258-64. PubMed ID: 20215772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes.
    Wurzburger MI; Prelevic GM; Sönksen PH; Balint-Peric LA; Wheeler M
    J Clin Endocrinol Metab; 1993 Jul; 77(1):267-72. PubMed ID: 8325951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.
    Jørgensen JO; Møller N; Lauritzen T; Alberti KG; Orskov H; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jan; 70(1):207-14. PubMed ID: 2294131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary growth hormone and insulin-like growth factor I. Effects of growth-hormone injection schedule.
    Albini CH; Quattrin T; Mills B; Sherman B; Johanson A; MacGillivray MH
    Clin Pediatr (Phila); 1992 Sep; 31(9):542-5. PubMed ID: 1468171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence studies for three formulations of a recombinant human growth hormone: challenges and lessons learned.
    Dao L; Jacobs J; Kuebler P; Bakker B; Lippe B
    Growth Horm IGF Res; 2010 Oct; 20(5):367-71. PubMed ID: 20708421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of human growth hormone administered subcutaneously with two different injection systems.
    de la Motte S; Klinger J; Kefer G; King T; Harrison F
    Arzneimittelforschung; 2001; 51(7):613-7. PubMed ID: 11505794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of moderate interval exercise versus supine rest on the pharmacokinetics and pharmacodynamic profiles of subcutaneously administered growth hormone in adult growth hormone deficient patients.
    Janukonytė J; Parkner T; Lauritzen T; Christiansen JS; Frystyk J; Pedersen HS; Laursen T
    Growth Horm IGF Res; 2014 Oct; 24(5):198-204. PubMed ID: 25037883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.